{"product_id":"lenvatinib-vs-atezolizumab-plus-bevacizumab-for-liver-cancer-that-cannot-be-surgically-removed-a-patient-friendly-guide-to-a-6-620-person-meta-analysis","title":"Lenvatinib vs. Atezolizumab Plus Bevacizumab for Liver Cancer That Cannot Be Surgically Removed: A Patient-Friendly Guide to a 6,620-Person Meta-Analysis","description":"\u003cp\u003eThis systematic review and meta-analysis pooled 12 studies and 6,620 patients. It compared two first-line treatments for unresectable hepatocellular carcinoma (HCC). HCC is the most common form of primary liver cancer, when the tumor cannot be removed by surgery. Lenvatinib (Lenvima) and the combination of atezolizumab plus bevacizumab (Tecentriq plus Avastin, often shortened to ATE\/BEV) produced similar overall survival. The two treatments also produced similar progression-free survival, objective response rates and disease control rates. There were no statistically significant differences in any of these measures. The two treatments also caused similar rates of serious (grade 3 or higher) side effects, high blood pressure and protein in the urine. However, lenvatinib was linked to more loss of appetite, diarrhea, fatigue and hand-foot syndrome. Hand-foot syndrome is redness, peeling and pain on the palms and soles. ATE\/BEV was linked to more cases of raised aspartate aminotransferase (AST). AST is a liver enzyme that leaks into the blood when liver cells are injured.\u003c\/p\u003e\n\n\u003ch1\u003eEfficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Question Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatments\"\u003eThe Two Treatments Being Compared\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-selection\"\u003eWhich Studies Were Included\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-characteristics\"\u003eWho Was in These Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#efficacy-os\"\u003eOverall Survival: No Clear Winner\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#efficacy-pfs\"\u003eProgression-Free Survival: No Clear Winner\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#response-rates\"\u003eTumor Response and Disease Control\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety-overview\"\u003eSerious Side Effects (Grade 3 or Higher)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety-details\"\u003eSpecific Side Effects: Where the Two Treatments Differ\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bias\"\u003eRisk of Bias and Publication Bias\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a review of 12 studies and 6,620 patients, lenvatinib and atezolizumab plus bevacizumab produced similar overall survival, progression-free survival, and tumor response, with no statistically significant differences.\u003c\/li\u003e\n\u003cli\u003eSerious side effects, high blood pressure, and protein in the urine occurred at similar rates with both treatments.\u003c\/li\u003e\n\u003cli\u003eLenvatinib was linked to more loss of appetite, diarrhea, fatigue, and hand-foot syndrome, while atezolizumab plus bevacizumab was linked to more raised aspartate aminotransferase.\u003c\/li\u003e\n\u003cli\u003eMost evidence was retrospective and came from Japan, Korea, and China, so results may not apply equally to all patients.\u003c\/li\u003e\n\u003cli\u003eNo head-to-head randomized trial exists; treatment choice should weigh liver function, overall health, and tolerance for specific side effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Question Matters\u003c\/h2\u003e\n\n\u003cp\u003eHepatocellular carcinoma (HCC) is the most common type of primary liver cancer — cancer that starts in the liver itself rather than spreading there from elsewhere. It begins when hepatocytes (the main liver cells) turn malignant. HCC accounts for roughly 85% of liver cancers in people diagnosed with cirrhosis (permanent scarring of the liver).\u003c\/p\u003e\n\n\u003cp\u003eThe disease is a major global health problem. In 2022 alone, doctors diagnosed more than \u003cstrong\u003e866,136 new cases\u003c\/strong\u003e of liver cancer worldwide, making it a leading cause of cancer deaths. Despite real progress in understanding what causes HCC, the overall 5-year survival rate remains very low — only about \u003cstrong\u003e5% to 14%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSurvival depends heavily on how far the cancer has spread. The 5-year survival rate is:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e33%\u003c\/strong\u003e when the cancer is localized (confined to one area)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e when it is regional (spread to nearby lymph nodes or tissues)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2%\u003c\/strong\u003e when it is metastatic (spread to distant organs)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther factors also shape how long a patient lives. These include portal vein thrombosis, a blood clot in the liver's main vein. They also include the size of the tumor and alpha-fetoprotein (AFP) levels, a protein in the blood used as a tumor marker. The tumor stage and how much liver damage the patient already has also matter. Patients with more extensive cirrhosis tend to have shorter survival times and fewer treatment options.\u003c\/p\u003e\n\n\u003cp\u003eDoctors usually diagnose HCC using non-invasive criteria — blood tests and imaging — rather than surgery. Tissue biopsy is being used more often in clinical practice. Prevention is possible for some patients: vaccines and antiviral medicines can protect against hepatitis B (HBV) and hepatitis C (HCV), the two viruses most strongly linked to liver cancer. Other major risk factors include heavy alcohol use, obesity, and non-alcoholic fatty liver disease (NAFLD, now often called MASLD — fat buildup in the liver not caused by alcohol).\u003c\/p\u003e\n\n\u003cp\u003eTreatment depends on the stage. For early-stage HCC, doctors may perform liver resection (surgery to remove part of the liver) or liver transplantation, both of which are considered curative. Local ablation with radiofrequency (using heat to destroy the tumor) can be an option when surgery is not needed. For intermediate-stage disease, transarterial chemoembolization (TACE — injecting chemotherapy directly into the tumor's blood supply) has been the standard of care for the past two decades.\u003c\/p\u003e\n\n\u003ch2 id=\"treatments\"\u003eThe Two Treatments Being Compared\u003c\/h2\u003e\n\n\u003cp\u003eFor unresectable HCC — cancer that cannot be removed by surgery — systemic therapies (treatments that travel through the bloodstream) are now the main option. These include immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and monoclonal antibodies (lab-made immune proteins that target specific molecules).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLenvatinib (LEN)\u003c\/strong\u003e is a multikinase inhibitor, a drug that blocks several enzymes at once. It targets pathways that HCC needs to grow and spread. One is the vascular endothelial growth factor (VEGF) pathway, which drives new blood vessel formation (angiogenesis). Another is the fibroblast growth factor (FGF) pathway, which drives tumor growth. In the phase III REFLECT trial, lenvatinib produced an average overall survival of \u003cstrong\u003e13.6 months\u003c\/strong\u003e with an acceptable safety profile.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAtezolizumab plus bevacizumab (ATE\/BEV)\u003c\/strong\u003e is a combination therapy that pairs two different mechanisms. Atezolizumab is a PD-L1 inhibitor — it blocks a signal that cancer cells use to hide from the immune system, so the body's immune response against the tumor gets stronger. Bevacizumab is a monoclonal antibody that blocks the VEGF pathway, cutting off the new blood vessels the tumor needs. In the phase III IMbrave150 trial, this combination extended overall survival and progression-free survival compared with sorafenib (an older liver cancer drug), reaching an average overall survival of \u003cstrong\u003e19.2 months\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the 13.6-month and 19.2-month figures come from two separate trials with different designs, not from a head-to-head comparison. Studies that directly compared lenvatinib with ATE\/BEV have produced inconsistent results. That inconsistency is exactly why this meta-analysis was performed.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Review\u003c\/h2\u003e\n\n\u003cp\u003eA meta-analysis is a study of studies. It combines the numbers from many separate studies into one overall result, which gives a more reliable answer than any single study alone. This review followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and was registered in advance in PROSPERO, an international database of planned reviews (ID CRD42024624039). Registering the plan up front helps prevent researchers from cherry-picking results later.\u003c\/p\u003e\n\n\u003cp\u003eThe team searched six databases — PubMed, ScienceDirect, Google Scholar, the Cochrane Library, SpringerLink, and Ebsco — for studies published up to July 2024. They used the keywords \"unresectable hepatocellular carcinoma\" or \"unresectable HCC,\" combined with \"Lenvatinib\" and \"Atezolizumab plus Bevacizumab\" and \"Efficacy\" and \"Safety.\" Two researchers performed the searches under the supervision of a senior investigator.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudies were included if they met these criteria:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eThey were randomized controlled trials (RCTs) with or without blinding, published in English, national or international — or observational studies (prospective or retrospective cohorts, case-control, or cross-sectional).\u003c\/li\u003e\n  \u003cli\u003eThey compared lenvatinib with atezolizumab plus bevacizumab.\u003c\/li\u003e\n  \u003cli\u003eThey enrolled adults aged 18 or older with a diagnosis of unresectable HCC.\u003c\/li\u003e\n  \u003cli\u003eThey reported at least one relevant outcome: overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), or side effects.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudies were excluded if they were:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eDuplicate publications\u003c\/li\u003e\n  \u003cli\u003eMissing a control group\u003c\/li\u003e\n  \u003cli\u003eConference abstracts or case reports\u003c\/li\u003e\n  \u003cli\u003eUnpublished\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers also attempted to obtain additional data by contacting the corresponding authors of the original studies.\u003c\/p\u003e\n\n\u003cp\u003eStudy quality was graded with the Newcastle-Ottawa Scale (NOS). The NOS scores observational studies from 0 to 9 across three areas. These areas are how the study groups were selected, how comparable the groups were, and how outcomes were assessed. Randomized trials would have been assessed with the Cochrane Risk-of-Bias tool (Version 2). This tool examines the randomization process, adherence to the planned treatment, and handling of missing data. It also examines accuracy of outcome measurement and selection of reported outcomes.\u003c\/p\u003e\n\n\u003cp\u003eData extracted from each study included: author name, publication year, country, study design, sample size, gender distribution, and age. It also included Child-Pugh class, a scoring system, A to C, for how well the liver is working. It also included ECOG score, a 0-to-5 scale for how much daily activity a patient can manage. It also included BCLC stage, the Barcelona Clinic Liver Cancer staging system.\u003c\/p\u003e\n\n\u003cp\u003eStatistical analysis used Review Manager (RevMan) 5.4 and RStudio version 2024.04.1. Results are reported as hazard ratios (HR) or odds ratios (OR) with 95% confidence intervals (CI). A confidence interval is the range in which the true value probably falls — if the range includes 1.0, the result is considered not statistically significant. Heterogeneity (how much the individual studies disagree with each other) was measured with the chi-squared (X²) and I² tests. When there was no meaningful heterogeneity (defined as P\u0026gt;0.1 or I²\u0026lt;50%), a fixed-effects model was used; otherwise a random-effects model was applied. Publication bias was checked with funnel plots, and the threshold for statistical significance was set at 0.05.\u003c\/p\u003e\n\n\u003ch2 id=\"study-selection\"\u003eWhich Studies Were Included\u003c\/h2\u003e\n\n\u003cp\u003eThe initial search turned up \u003cstrong\u003e930 records\u003c\/strong\u003e. The review team then narrowed them down step by step:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003e39 articles\u003c\/strong\u003e were removed because they were duplicates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e686 studies\u003c\/strong\u003e were discarded after the researchers read their titles and abstracts.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e165 articles\u003c\/strong\u003e were excluded after full-text review because they did not match the inclusion and exclusion criteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e27 studies\u003c\/strong\u003e were dropped because they lacked the relevant data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e12 articles\u003c\/strong\u003e were ultimately included in the analysis.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"study-characteristics\"\u003eWho Was in These Studies\u003c\/h2\u003e\n\n\u003cp\u003eThe 12 included studies enrolled a total of \u003cstrong\u003e6,620 participants\u003c\/strong\u003e. Of these, \u003cstrong\u003e3,745\u003c\/strong\u003e received lenvatinib and \u003cstrong\u003e2,875\u003c\/strong\u003e received atezolizumab plus bevacizumab.\u003c\/p\u003e\n\n\u003cp\u003eThe studies were published between 2022 and 2024. Every included study used a cohort design, following a group of patients over time. Most were retrospective. This means the researchers looked back at medical records rather than enrolling patients in advance. Only one study had a prospective design (following patients forward in time). Three studies were multicenter, meaning they collected data from more than one hospital or institution. Six studies came from Japan, two from Korea, and one from China.\u003c\/p\u003e\n\n\u003cp\u003eMost patients in the pooled studies had Child-Pugh class A, meaning their liver function was relatively preserved. Most also had an ECOG score of 0, meaning they were fully active and able to carry out normal daily activities without restriction. By BCLC category, most patients fell into category B (intermediate-stage disease).\u003c\/p\u003e\n\n\u003cp\u003eQuality scores on the Newcastle-Ottawa Scale ranged from \u003cstrong\u003e7 to 9\u003c\/strong\u003e, which the authors describe as indicating high-quality data across all included studies. Studies were reported by Kimura (2024, Japan), Park (2024, Korea), Persano (2023, multicenter), Maesaka (2022, Japan, prospective), Gardini (2023, multicenter), Hatanaka (2023, Japan), Muto (2023, Japan), Niizeki (2022, Japan), Kim (2022, Korea), Hiraoka (2022, Japan), Su (2022, China), and Rimmini (2022, multicenter).\u003c\/p\u003e\n\n\u003ch2 id=\"efficacy-os\"\u003eOverall Survival: No Clear Winner\u003c\/h2\u003e\n\n\u003cp\u003eThe key finding on overall survival (how long patients lived) is that there was no statistically significant difference between the two treatments. Three studies reported OS.\u003c\/p\u003e\n\n\u003cp\u003eThe combined hazard ratio was \u003cstrong\u003e0.72\u003c\/strong\u003e with a 95% confidence interval of \u003cstrong\u003e0.44 to 1.18\u003c\/strong\u003e and a p-value of \u003cstrong\u003e0.20\u003c\/strong\u003e. In plain terms, a hazard ratio below 1.0 would favor lenvatinib, but because the confidence interval crosses 1.0 and the p-value is above 0.05, this difference could easily be due to chance. A random-effects model was used because the studies differed substantially from one another (p = 0.04, I² = 69%, indicating moderate-to-high heterogeneity).\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also looked separately at patients whose HCC was linked to a viral infection (hepatitis B or C) and those whose cancer was not virus-related.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn patients with viral infection\u003c\/strong\u003e (3 studies), the hazard ratio was \u003cstrong\u003e0.75\u003c\/strong\u003e (95% CI: 0.46–1.22, p = 0.24) — no significant difference. A fixed-effects model was used because the studies agreed closely (p = 0.63, I² = 0%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIn patients without viral infection\u003c\/strong\u003e (3 studies), the hazard ratio was \u003cstrong\u003e0.81\u003c\/strong\u003e (95% CI: 0.25–2.56, p = 0.72) — again, no significant difference. Here the confidence interval is very wide, spanning from strongly favoring lenvatinib to strongly favoring ATE\/BEV. A random-effects model was used because the studies disagreed a great deal (p = 0.0005, I² = 87%).\u003c\/p\u003e\n\n\u003ch2 id=\"efficacy-pfs\"\u003eProgression-Free Survival: No Clear Winner\u003c\/h2\u003e\n\n\u003cp\u003eProgression-free survival (PFS) measures how long patients lived without their cancer getting worse. Four studies reported this outcome.\u003c\/p\u003e\n\n\u003cp\u003eThe pooled hazard ratio was \u003cstrong\u003e0.90\u003c\/strong\u003e (95% CI: 0.75–1.07, p = \u003cstrong\u003e0.23\u003c\/strong\u003e), meaning no statistically significant difference between lenvatinib and ATE\/BEV. Once again, the confidence interval crosses 1.0. The authors report that a fixed-effects model was used, with heterogeneity present (p = 0.04, I² = 68%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePFS in patients with viral infection\u003c\/strong\u003e (3 studies): hazard ratio \u003cstrong\u003e0.84\u003c\/strong\u003e (95% CI: 0.60–1.16, p = 0.29) — no significant difference and very consistent results across studies (p = 0.94, I² = 0%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePFS in patients without viral infection\u003c\/strong\u003e (3 studies): hazard ratio \u003cstrong\u003e0.89\u003c\/strong\u003e (95% CI: 0.46–1.74, p = 0.74) — no significant difference, with substantial disagreement among the studies (p = 0.04, I² = 68%).\u003c\/p\u003e\n\n\u003cp\u003eTogether, these subgroup results suggest that the cause of a patient's liver cancer — viral or non-viral — does not change how these two treatments compare.\u003c\/p\u003e\n\n\u003ch2 id=\"response-rates\"\u003eTumor Response and Disease Control\u003c\/h2\u003e\n\n\u003cp\u003eTwo additional measures describe how the tumors themselves responded.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eObjective response rate (ORR)\u003c\/strong\u003e is the percentage of patients whose tumor shrank measurably or disappeared. Eight studies reported ORR. The pooled odds ratio was \u003cstrong\u003e1.16\u003c\/strong\u003e (95% CI: 0.86–1.56, p = \u003cstrong\u003e0.34\u003c\/strong\u003e) — no significant difference between the two drugs. A random-effects model was used because the studies varied (p = 0.008, I² = 63%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisease control rate (DCR)\u003c\/strong\u003e is the percentage of patients whose cancer either shrank or stayed stable — that is, did not progress. Seven studies reported DCR. The pooled odds ratio was \u003cstrong\u003e1.14\u003c\/strong\u003e (95% CI: 0.97–1.34, p = \u003cstrong\u003e0.12\u003c\/strong\u003e) — no significant difference, though the result leaned slightly toward lenvatinib. A fixed-effects model was used (p = 0.07, I² = 49%).\u003c\/p\u003e\n\n\u003cp\u003eBecause the confidence interval here runs from 0.97 to 1.34, a very small advantage for one drug cannot be ruled out — but the result did not reach statistical significance.\u003c\/p\u003e\n\n\u003ch2 id=\"safety-overview\"\u003eSerious Side Effects (Grade 3 or Higher)\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers graded side effects using standard cancer trial categories, where grade 1 is mild and grade 5 is fatal. Serious adverse events of grade 3 or higher are those that interfere significantly with daily life or require medical intervention.\u003c\/p\u003e\n\n\u003cp\u003eThree studies reported grade 3 or higher adverse events. The pooled odds ratio was \u003cstrong\u003e1.15\u003c\/strong\u003e (95% CI: \u003cstrong\u003e0.29–4.55\u003c\/strong\u003e, p = \u003cstrong\u003e0.84\u003c\/strong\u003e) — essentially identical between the two groups. The confidence interval is extremely wide, which reflects how much the individual studies disagreed (p = 0.0007, I² = 86%). This wide range means the analysis cannot rule out meaningful differences in either direction for severe side effects overall.\u003c\/p\u003e\n\n\u003ch2 id=\"safety-details\"\u003eSpecific Side Effects: Where the Two Treatments Differ\u003c\/h2\u003e\n\n\u003cp\u003eThis is where the two treatments look most different. Lenvatinib was associated with more of several common side effects, while ATE\/BEV was associated with more of one liver-related side effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSide effects that were MORE common with lenvatinib:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDecreased appetite\u003c\/strong\u003e (5 studies): odds ratio \u003cstrong\u003e2.95\u003c\/strong\u003e (95% CI: 1.12–7.79, p = \u003cstrong\u003e0.03\u003c\/strong\u003e). This was statistically significant, meaning the odds of losing appetite were roughly three times higher with lenvatinib. Heterogeneity was high (p = 0.0003, I² = 81%).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiarrhea\u003c\/strong\u003e (6 studies): odds ratio \u003cstrong\u003e2.61\u003c\/strong\u003e (95% CI: 2.06–3.32, p \u003cstrong\u003e\u0026lt; 0.00001\u003c\/strong\u003e). Highly significant, with studies agreeing closely (p = 0.62, I² = 49%).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFatigue\u003c\/strong\u003e (5 studies): odds ratio \u003cstrong\u003e1.48\u003c\/strong\u003e (95% CI: 1.27–1.73, p \u003cstrong\u003e\u0026lt; 0.00001\u003c\/strong\u003e). Highly significant and very consistent across studies (p = 0.92, I² = 0%).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHand-foot syndrome\u003c\/strong\u003e (4 studies): odds ratio \u003cstrong\u003e7.73\u003c\/strong\u003e (95% CI: 4.84–12.33, p \u003cstrong\u003e\u0026lt; 0.00001\u003c\/strong\u003e). This was the largest difference found in the entire review. Hand-foot syndrome — also called palmar-plantar erythrodysesthesia — causes redness, swelling, peeling, blisters, and pain on the palms of the hands and soles of the feet. Results were very consistent (p = 0.78, I² = 0%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSide effects that were MORE common with ATE\/BEV:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncreased aspartate aminotransferase (AST)\u003c\/strong\u003e (3 studies): odds ratio \u003cstrong\u003e0.44\u003c\/strong\u003e (95% CI: 0.28–0.69, p = \u003cstrong\u003e0.0004\u003c\/strong\u003e). An odds ratio below 1.0 favors lenvatinib here. This means patients on ATE\/BEV were roughly twice as likely to show elevated AST. AST is a liver enzyme that rises when liver cells are damaged. Studies agreed closely (p = 0.41, I² = 0%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSide effects that were SIMILAR between the two treatments:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypertension (high blood pressure)\u003c\/strong\u003e (7 studies): odds ratio \u003cstrong\u003e1.39\u003c\/strong\u003e (95% CI: 0.84–2.28, p = \u003cstrong\u003e0.20\u003c\/strong\u003e). No significant difference. The studies disagreed substantially (p \u0026lt; 0.00001, I² = 85%).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProteinuria (protein leaking into the urine)\u003c\/strong\u003e (5 studies): odds ratio \u003cstrong\u003e1.10\u003c\/strong\u003e (95% CI: 0.75–1.60, p = \u003cstrong\u003e0.63\u003c\/strong\u003e). No significant difference. Moderate inconsistency between studies (p = 0.07, I² = 54%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAn important caution applies to all of these numbers. Odds ratios describe relative differences in risk — they do not tell you how many patients out of 100 will actually experience a side effect. The original studies did not consistently report absolute percentages, so this review cannot say \"X in Y patients on lenvatinib developed diarrhea.\"\u003c\/p\u003e\n\n\u003ch2 id=\"bias\"\u003eRisk of Bias and Publication Bias\u003c\/h2\u003e\n\n\u003cp\u003ePublication bias happens when studies with positive or dramatic results are more likely to be published than studies showing no difference. Funnel plot analysis was used to check for this.\u003c\/p\u003e\n\n\u003cp\u003eThe analysis flagged three variables as having a potential for publication bias:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eProgression-free survival (PFS)\u003c\/li\u003e\n  \u003cli\u003eDisease control rate (DCR)\u003c\/li\u003e\n  \u003cli\u003eDiarrhea\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors attribute part of this to the relative newness of the research — there simply are not yet enough studies to produce a reliable funnel plot for every outcome. Funnel plots need many studies to be trustworthy, and most comparisons here included only three to eight studies.\u003c\/p\u003e\n\n\u003cp\u003eFor most variables, however, the funnel plots showed a symmetric distribution, which suggests a low risk of publication bias. The review's own quality assessment found Newcastle-Ottawa Scale scores of 7 to 9 out of 9 across all included studies.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe headline conclusion is that lenvatinib is \u003cstrong\u003enon-inferior\u003c\/strong\u003e to atezolizumab plus bevacizumab. \"Non-inferior\" is a research term meaning the treatment is not meaningfully worse — it may be roughly as good. Across four separate measures of how well the drugs fight cancer, the two performed similarly.\u003c\/p\u003e\n\n\u003cp\u003eThat said, the individual hazard ratios for OS (0.72) and PFS (0.90) both fell below 1.0, numerically favoring lenvatinib, even though neither reached statistical significance. The authors do not draw a firm conclusion from this. The wide confidence intervals — especially the OS non-viral subgroup range of 0.25 to 2.56 — mean the data simply cannot distinguish a real difference from noise.\u003c\/p\u003e\n\n\u003cp\u003eThe safety picture is more clearly separated. Lenvatinib showed higher rates of several bothersome side effects, particularly hand-foot syndrome, diarrhea, fatigue, and decreased appetite. These are often manageable but can affect quality of life and may lead to dose reductions. Atezolizumab plus bevacizumab showed a higher rate of elevated AST, a marker of liver irritation — a concern in patients whose livers are already compromised by cirrhosis.\u003c\/p\u003e\n\n\u003cp\u003eNotably, rates were similar for the most feared outcomes: severe grade 3 or higher adverse events, high blood pressure, and protein in the urine. These are the toxicities doctors watch most closely in this patient population.\u003c\/p\u003e\n\n\u003cp\u003eThe practical takeaway is that there is no single \"best\" drug for everyone. Treatment choice should weigh tumor factors, liver function (Child-Pugh class), and overall fitness (ECOG score). It should also weigh the cause of the liver disease (viral versus non-viral) and each patient's tolerance for specific side effects.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eSeveral important limitations temper these findings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAlmost all the evidence was retrospective.\u003c\/strong\u003e Only one of the 12 studies was prospective. Retrospective studies look backward at existing records, and doctors may have chosen one drug over the other based on how sick a patient was. This kind of selection bias can distort comparisons, and the review's statistical methods cannot fully correct for it.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe evidence was concentrated in specific countries.\u003c\/strong\u003e Six studies came from Japan, two from Korea, and one from China. Results may not apply equally to patients in other regions with different patterns of liver disease, different genetic backgrounds, and different standards of care.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSeveral analyses showed high heterogeneity.\u003c\/strong\u003e The I² statistic measures what percentage of the variation between studies is due to real differences rather than chance. Values above 50% are considered substantial. Some analyses here reached 81%, 85%, 86%, and even 87%. When studies disagree this much, the combined estimate is less trustworthy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSome pooled estimates were imprecise.\u003c\/strong\u003e The wide confidence interval for grade 3 or higher adverse events (0.29 to 4.55) means the review genuinely cannot tell whether severe side effects differ between the drugs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication bias could not be fully excluded\u003c\/strong\u003e for progression-free survival, disease control rate, and diarrhea.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo head-to-head randomized trial exists.\u003c\/strong\u003e The 13.6-month survival figure for lenvatinib came from the REFLECT trial and the 19.2-month figure for ATE\/BEV came from IMbrave150. These are different trials with different patient populations, so directly comparing them is misleading. Only a randomized trial that assigns patients to one drug or the other could answer that question definitively.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eIf you or someone you care for is facing a decision about first-line treatment for unresectable HCC, here is what this review supports:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your oncology team why a specific drug is being recommended for you.\u003c\/strong\u003e Because the two options performed similarly on survival and tumor response, the decision often comes down to your liver function. It also comes down to your overall health and which side effects you are best able to tolerate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss side effect profiles in advance.\u003c\/strong\u003e If you have a history of gut problems, ask about diarrhea risk with lenvatinib. If your liver function is already fragile, ask how your team will monitor for AST elevation on ATE\/BEV.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReport hand-foot syndrome early.\u003c\/strong\u003e With an odds ratio of 7.73, this is by far the most common lenvatinib-specific problem. Early reports of tingling, redness, or tenderness on the palms and soles allow your team to adjust doses or recommend moisturizers and cooling measures before symptoms become severe.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect monitoring for blood pressure and urine protein.\u003c\/strong\u003e Both drugs can affect these, and both are checked routinely during treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e The authors note that head-to-head randomized data are still lacking. A trial that directly compares these two regimens would give patients far more certainty than the current retrospective evidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop or change treatment on your own.\u003c\/strong\u003e These findings describe population-level averages. Your individual situation — tumor stage, liver reserve, prior treatments — matters more than any pooled statistic.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is unresectable hepatocellular carcinoma?\u003c\/h3\u003e\n\u003cp\u003eHepatocellular carcinoma is the most common type of primary liver cancer, starting in the liver's main cells. It is called unresectable when the tumor cannot be removed by surgery. For these patients, systemic treatments that travel through the bloodstream are the main option, including lenvatinib and the combination of atezolizumab plus bevacizumab.\u003c\/p\u003e\n\u003ch3\u003eHow do lenvatinib and atezolizumab plus bevacizumab compare for survival?\u003c\/h3\u003e\n\u003cp\u003eIn a review of 12 studies and 6,620 patients, overall survival and progression-free survival were similar between lenvatinib and atezolizumab plus bevacizumab, with no statistically significant differences. The combined hazard ratios were 0.72 for overall survival and 0.90 for progression-free survival, but both confidence intervals crossed 1.0, meaning the differences could be due to chance.\u003c\/p\u003e\n\u003ch3\u003eWhich treatment has more side effects?\u003c\/h3\u003e\n\u003cp\u003eBoth treatments caused similar rates of serious side effects, high blood pressure, and protein in the urine. However, lenvatinib was linked to more loss of appetite, diarrhea, fatigue, and hand-foot syndrome. Atezolizumab plus bevacizumab was linked to more cases of raised aspartate aminotransferase. Aspartate aminotransferase is a liver enzyme that rises when liver cells are injured.\u003c\/p\u003e\n\u003ch3\u003eDoes it matter if my liver cancer is caused by hepatitis B or C?\u003c\/h3\u003e\n\u003cp\u003eThe review looked separately at patients whose cancer was linked to viral infection and those whose cancer was not. In both groups, overall survival and progression-free survival were similar between lenvatinib and atezolizumab plus bevacizumab, with no statistically significant differences. This suggests the cause of the liver cancer does not change how these two treatments compare.\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio of 0.72 mean?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio compares the risk of an event, such as death, between two treatments. A value below 1.0 would favor lenvatinib, but the 95% confidence interval was 0.44 to 1.18, which crosses 1.0. Because the interval includes 1.0 and the p-value was 0.20, the difference in overall survival could easily be due to chance.\u003c\/p\u003e\n\u003ch3\u003eShould I ask my doctor about clinical trials?\u003c\/h3\u003e\n\u003cp\u003eYes. The review authors note that no head-to-head randomized trial directly compares lenvatinib with atezolizumab plus bevacizumab. The 13.6-month and 19.2-month survival figures come from two separate trials with different designs, so comparing them directly is misleading. A trial that assigns patients to one regimen or the other would give far more certainty.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with inoperable liver cancer (unresectable HCC) seek a second opinion before starting lenvatinib or atezolizumab plus bevacizumab?\u003c\/h3\u003e\n\u003cp\u003eLenvatinib and atezolizumab plus bevacizumab produced similar overall survival, progression-free survival, tumor response and disease control. There were no statistically significant differences. The choice often rests on liver function, overall fitness and which side effects a patient can tolerate. A second opinion can help weigh these factors, since lenvatinib carries more loss of appetite, diarrhea, fatigue and hand-foot syndrome, while the combination carries more raised AST. Seeking one is reasonable before committing to a first-line regimen, particularly when liver function is fragile or the tumor and cirrhosis details are complex. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Ni Putu Sri Indrani Remitha, Ni Putu Rista Pradnya Dewi, Komang Wira Ananta Kusuma, I Gede Aswin Parisya Sasmana, I Gede Putu Supadmanaba, Dwijo Anargha Sindhughosa, and I Ketut Mariadi\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia; Department of Biochemistry, Faculty of Medicine, Udayana University; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Udayana University; and Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Udayana University \/ Prof. Ngoerah Hospital, Bali, Indonesia\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Asian Pacific Journal of Cancer Prevention (Asian Pac J Cancer Prev), Volume 26, Issue 5, pages 1529–1542\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.31557\/APJCP.2025.26.5.1529\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication timeline:\u003c\/strong\u003e Submitted January 2, 2025; accepted May 15, 2025\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegistration:\u003c\/strong\u003e PROSPERO ID CRD42024624039\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e Atezolizumab, bevacizumab, hepatocellular carcinoma, lenvatinib\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace personalized medical advice. Treatment decisions for hepatocellular carcinoma should always be made in consultation with a qualified oncology and hepatology team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576761172124,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/zh\/products\/lenvatinib-vs-atezolizumab-plus-bevacizumab-for-liver-cancer-that-cannot-be-surgically-removed-a-patient-friendly-guide-to-a-6-620-person-meta-analysis","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}